연구동향 분석
박사

Population pharmacokinetic/pharmacodynamic modeling of drugs for cardiovascular disease: S-amlodipine and triflusal : 건강한 한국 남성 자원자에서 심혈관 질환 치료제(암로디핀, 트리플루살)의 집단 약동/약력학 모델링

박성민 2015년

논문상세정보
인용/피인용
' Population pharmacokinetic/pharmacodynamic modeling of drugs for cardiovascular disease: S-amlodipine and triflusal : 건강한 한국 남성 자원자에서 심혈관 질환 치료제(암로디핀, 트리플루살)의 집단 약동/약력학 모델링' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • cardiovascular disease
  • nonmem
  • population pharmacokinetics and pharmacodynamics
  • s-amlodipine
  • triflusal
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
130 0

0.0%

' Population pharmacokinetic/pharmacodynamic modeling of drugs for cardiovascular disease: S-amlodipine and triflusal : 건강한 한국 남성 자원자에서 심혈관 질환 치료제(암로디핀, 트리플루살)의 집단 약동/약력학 모델링' 의 참고문헌

  • de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A:ontogeny and drug disposition. Clin Pharmacokinet 1999,37:485-505.
  • Zuo XC, Zhang WL, Yuan H, et al. ABCB1 polymorphism andgender affect the pharmacokinetics of amlodipine in Chinesepatients with essential hypertension: a population analysis. DrugMetab Pharmacokinet 2014, 29:305-311.
  • Zhou L, Schmaier AH. Platelet aggregation testing in platelet-richplasma: description of procedures with the aim to developstandards in the field. Am J ClinPathol 2005, 123:172-183.
  • Zhang XP, Loke KE, Mital S, et al. Paradoxical release of nitricoxide by an L-type calcium channel antagonist, the R+enantiomer of amlodipine. J Cardiovasc Pharmacol 2002,39:208-214.
  • Yim DS, Han SH, Lee JT, et al. In Catholic PK/PD School.84Department of clinical pharmacology and therapeutics, SeoulST.MARY s Hospital 2011.
  • WHO. Global health risks: Mortality and burden of diseaseattributable to selected major risks. Geneva, World HealthOrganization (WHO), 2009.
  • WHO, World Heart Federation, World Stroke Organization.85Global Atlas on cardiovascular disease prevention and control.2011.
  • Valle M, Barbanoj MJ, Donner A, et al. Access of HTB, mainmetabolite of triflusal, to cerebrospinal fluid in healthy volunteers.Eur J Clin Pharmacol 2005, 61:103-111.
  • Stanski DR, Maitre PO. Population pharmacokinetics andpharmacodynamics of thiopental: the effect of age revisited.Anesthesiology 1990, 72:412-422 .
  • Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modelingof pharmacokinetics and pharmacodynamics: application to dtubocurarine.Clin Pharmacol Ther 1979, 25:358-371.
  • Sheiner LB, Rosenberg B, Melmon KL. Modelling of individualpharmacokinetics for computer-aided drug dosage. ComputBiomed Res 1972, 5:411-459.
  • Sheiner LB, Beal SL. Evaluation of methods for estimatingpopulation pharmacokinetic parameters. II. Biexponential modeland experimental pharmacokinetic data. J PharmacokinetBiopharm 1981, 9:635-651.
  • Sheiner LB, Beal SL, Rosenberg B, et al. Forecasting individualpharmacokinetics. Clin Pharmacol Ther 1979, 26:294-305.83
  • Rao GH, Reddy KR, White JG. Effect of acetaminophen andsalicylate on aspirin-induced inhibition of human platelet cyclooxygenase.Prostaglandins Leukot Med 1982, 9:109-115.
  • Ramis J, Mis R, Forn J, et al. Pharmacokinetics of triflusal and itsmain metabolite HTB in healthy subjects following a single oraldose. Eur J Drug Metab Pharmacokinet 1991, 16:269-273.
  • Pimenta E, Oparil S. Fixed combinations in the management ofhypertension: patient perspectives and rationale for developmentand utility of the olmesartan-amlodipine combination. VascHealth Risk Manag 2008, 4:653-664.
  • Peter A. Meredith, Dr Henry L. Elliott. Clinical Pharmacokineticsof Amlodipine. Clinical Pharmacokinetics 1992, 22:22-31
  • Peck CC, Barrett BB. Nonlinear least-squares regressionprograms for microcomputers. J Pharmacokinet Biopharm 1979,7:537-541.
  • Park JY, Kim KA, Park PW, et al. Pharmacokinetic andpharmacodynamic characteristics of a new S-amlodipineformulation in healthy Korean male subjects: a randomized,open-label, two-period, comparative, crossover study. Clin Ther2006, 28:1837-1847.
  • Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologiceffects in man: the anticoagulant action of warfarin. ClinPharmacol Ther 1969, 10:22-35.
  • Murdoch D, PloskerGL. Triflusal: a review of its use in cerebralinfarction and myocardial infarction, and as thromboprophylaxisin atrial fibrillation. Drugs 2006, 66:671-692.
  • Mould DR, Upton RN. Basic Concepts in Population Modeling,Simulation, and Model-Based Drug Development. CPTPharmacometrics Syst Pharmacol 2012, 1:e6.
  • McNeely W, Goa KL. Triflusal. Drugs 1998, 7:823-833.
  • Matias-Guiu J, Ferro JM, Alvarez-Sabin J, et al. Comparison oftriflusal and aspirin for prevention of vascular events in patientsafter cerebral infarction: the TACIP Study: a randomized, doubleblind,multicenter trial. Stroke 2003, 34:840-848.
  • Liu Y, Jia J, Liu G, et al. Pharmacokinetics and bioequivalenceevaluation of two formulations of 10-mg amlodipine besylate: anopen-label, single-dose, randomized, two-way crossover study inhealthy Chinese male volunteers. Clin Ther 2009, 31:777-783.
  • Lee JY, Garnett CE, Gobburu JV, et al. Impact of pharmacometricanalyses on new drug approval and labelling decisions: a reviewof 198 submissions between 2000 and 2008. Clin Pharmacokinet2011, 50:627-635.
  • Lee HW, Lim MS, SeongSJ, et al. A phase I study to characterizethe multiple-dose pharmacokinetics, pharmacodynamics andsafety of new enteric-coated triflusal formulations in healthy malevolunteers. Expert Opin Drug Metab Toxicol 2011, 7:1471-1479.
  • L Matyska, J Kovar. Comparison of several non-linear-regressionmethods for fitting the Michaelis-Menten equation. Biochem J1985, 231: 171-177.
  • Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3Apromoters and characterization of the genetic basis ofpolymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
  • Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3genotype on the stereoselective pharmacokinetics of amlodipinein healthy subjects. Chirality 2009, 21:485-491.
  • Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotypeon the pharmacokinetics and pharmacodynamics of amlodipinein healthy Korean subjects. Clin Pharmacol Ther 2006, 80:646-656.87
  • Jonsson EN, KarlssonMO. Xpose--an S-PLUS based populationpharmacokinetic/pharmacodynamic model building aid forNONMEM. Comput Methods Programs Biomed 1999, 58:51-64.
  • Joel S. Owen, Jill Fiedler-Kelly. Introduction to PopulationPharmacokinetic / Pharmacodynamic Analysis with NonlinearMixed Effects Models. 1st edition. New York: Wiley; 2014:251.
  • Instruction manual for the chrono-log model 490 optical91aggregometers. Chrono-log, Havertown, PA, USA.
  • Institute of Medicine of the National. Promoting cardiovascularhealth in the developing world : a critical challenge to achieveglobal health. Washington, D.C.: National Academies Press;2010.
  • Holford NH, Sheiner LB. Kinetics of pharmacologic response.Pharmacol Ther 1982, 16:143-166.
  • Harrison P, Mackie I, Mumford A, et al. Guidelines for thelaboratory investigation of heritable disorders of platelet function.Br J Haematol 2011, 155:30-44.
  • Guidance for Industry: Population Pharmacokinetics. Food andDrug Administration, May 2003.
  • Guidance for Industry: Exposure-response relationships, studydesign, data analysis and regulatory applications. Food and DrugAdministration, May 2003.
  • Goutelle S, Maurin M, Rougier F, et al. The Hill equation: areview of its capabilities in pharmacological modelling. FundamClin Pharmacol 2008, 22:633-648.
  • Gonzalez-Correa JA, De La Cruz JP. Triflusal: an antiplateletdrug with a neuroprotective effect? Cardiovasc Drug Rev 2006,24:11-24.
  • Gabrielsson J, Weiner D. Pharmacodynamic Concepts. InPharmacokinetic and Pharmacodynamic Data Analysis:Concepts and Applications. 4th edition. Stockholm: SwedishPharmaceutical Press; 2007:265.
  • Flynn JT, Nahata MC, Mahan JD Jr, et al. Populationpharmacokinetics of amlodipine in hypertensive children andadolescents. J Clin Pharmacol 2006, 46:905-916.
  • Dong HP, Wu HM, Chen SJ, etal. The effect of butanolides fromCinnamomum tenuifolium on platelet aggregation. Molecules2013, 18:11836-11841.
  • Dennis F, Steven S. Fisher/Shafer NONMEM WorkshopPharmacokinetic and Pharmacodynamic Analysis with NONMEM.Feb 2008.
  • Dayneka NL, Garg V, Jusko WJ. Comparison of four basicmodels of indirect pharmacodynamics responses. JPharmacokinet Biopharm 1993, 21:457-478.
  • Csajka C, Buclin T, Fattinger K, et al. Populationpharmacokinetic-pharmacodynamic modelling of angiotensinreceptor blockade in healthy volunteers. Clin Pharmacokinet2002, 41:137-152.
  • Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventingserious vascular events in people at high risk. Cochrane86Database Syst Rev 2005, 20:CD004296.
  • Cho HY, Jeong TJ, Lee YB. Simultaneous determination oftriflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by highperformanceliquid chromatography. J Chromatogr B AnalytTechnol Biomed Life Sci 2003, 798:257-264.
  • Casella G, Berger RL. Regression Models. In Statistical Inference.2nd edition. California: Wadsworth; 2001:592.
  • Bosca F, Cuquerella MC, Marin ML, et al. Photochemistry of 2-hydroxy-4-trifluoromethylbenzoic acid, major metabolite of thephotosensitizing platelet antiaggregant drug triflusal. PhotochemPhotobiol 2001, 73:463-468.
  • Beal S, Sheiner L. NONMEM User's Guide Part I. San Francisco:University of California at San Francisco; 1992.
  • Bayon Y, Alonso A, Sanchez Crespo M.4-trifluoromethylderivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of90nuclear factor kappaB activation. Br J Pharmacol 1999,126:1359-1366.
  • Anninos H, Andrikopoulos G, Pastromas S, etal. Triflusal: an olddrug in modern antiplatelet therapy. Review of its action, use,safety and effectiveness. Hellenic J Cardiol 2009, 50:199-207.89
  • Agresti A. Logistic Regression. In Categorical Data Analysis. 2ndedition. New York: Wiley; 2002:166.
  • Adik-Pathak L. Chiral molecules in hypertension: focus on Samlodipine.J Assoc Physicians India 2004, 52:187-188.88
  • ?1. Gobburu JV. Pharmacometrics 2020. J Clin Pharmacol 2010,50:151S-157S.